

New Treatment Available at Holcomb-Kreithen Plastic Surgery and MedSpa

Now Offering KYBELLA™, the First and Only Injectable Drug for Submental Fullness, or Double Chin.

Sarasota, Florida ([PRWEB](#)) August 14, 2015 -- KYBELLA™ (deoxycholic acid) injection, the first and only FDA-approved injectable drug available that contours and improves the appearance of moderate to severe submental fullness, sometimes referred to as a “double chin,” is now available in Sarasota. Submental fullness is a common, yet under-treated aesthetic condition that is often resistant to diet and exercise alone and influenced by several factors, including aging, genetics and weight gain.

“We are excited to be one of the first plastic surgery offices in southwest Florida to be able to offer KYBELLA™ to patients. We are excited about this new treatment and believe that it will benefit the lives of our patients,” said Dr. J. David Holcomb, Double Board Certified Facial Plastic Surgeon at Holcomb-Kreithen Plastic Surgery and MedSpa. Each in-office treatment session with KYBELLA™ is typically 15-20 minutes. When injected into subcutaneous fat, KYBELLA™ causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. After the aesthetic response is achieved with KYBELLA™, re-treatment is not expected. With this nonsurgical treatment, many patients experience visible results in two to four treatment sessions spaced at least one month apart. Up to six treatments may be administered. Treatment with KYBELLA™ is customized the patient’s aesthetic goals for an improved chin profile.

The most common side effects are swelling, bruising, pain, numbness, redness and formation of areas of hardness in the treatment area. In clinical trials, the incidence and severity of most side effects decreased with subsequent KYBELLA™ treatments. KYBELLA™ can cause serious side effects, including trouble swallowing and nerve injury in the jaw that can cause an uneven smile or facial muscle weakness. KYBELLA™ has been the focus of a global clinical development program involving over 20 clinical studies with more than 2,600 patients world wide, of which 1,600 have been treated with KYBELLA™ . To learn more, please visit <http://www.sarasota-med.com> or <http://www.mykybella.com>.

About Holcomb-Kreithen Plastic Surgery and MedSpa (www.sarasota-med.com)

Holcomb-Kreithen Plastic Surgery and MedSpa is located downtown Sarasota and occupies the newly renovated 8th floor of the Kane Plaza. The founding physicians include J. David Holcomb, MD (Facial Plastic and Cosmetic Laser Surgeon) and Joshua Kreithen, MD (Breast and Body Contouring Specialist). The AAAASF accredited facility includes a private ambulatory surgical center and the H | K MedSpa (www.sarasota-med.com) is among the most comprehensive in Florida with many options for minimally invasive and non-surgical contouring of the face and body, state-of-the-art laser and skin care centers and an Aesthetic and Wellness Medicine specialist, Dr. Andrea Kreithen, to help patients refine their appearance and optimize their inner physical well being.

About KYBELLA™

KYBELLA™ is the first and only approved injectable drug for contouring moderate to severe submental fullness, a condition that is commonly referred to as a double chin. KYBELLA™ is a non-human and non-animal formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into subcutaneous fat, KYBELLA™ causes the destruction of fat

cells. Once destroyed, those cells cannot store or accumulate fat.ii KYBELLA™ (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. The safe and effective use of KYBELLA™ for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

**Contact Information****J. David Holcomb**

Holcomb-Kreithen Plastic Surgery and MedSpa

<http://www.sarasota-med.com>

+1 (941) 365-8679

Online Web 2.0 VersionYou can read the online version of this press release [here](#).